Opinion
Video
Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
Author(s):
The panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.
EP: 1.Overview of pLGG presentation and categorization
EP: 2.Molecular Characterization of pLGG
EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations
EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors
EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
EP: 6.Current Treatment of Patients with NF1 pLGG
Now Viewing
EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
EP: 8.Treatment Considerations for Progressive pLGG
EP: 9.Radiation and Targeted Therapies for Progressive pLGG
EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG
EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting
EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion
EP: 13.Alternatives and Considerations for Clinical Scenario 1
EP: 14.Clinical Scenario 2 - BRAFV600E
EP: 15.Potential Adverse Events With Targeted Therapies
EP: 16.Clinical Insights: Looking Forward for pLGG
- Briefly describe the standard of care options specific for frontline treatment of BRAF V600E-mutated pLGG
Related Videos
Related Content
